Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Losmapimod 15 mg Tablet
NCT05002231Phase 1Completed
- Sponsor
- Fulcrum Therapeutics
- Start
- Aug 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) (3 arms), sponsored by Fulcrum Therapeutics. Primary endpoints: Plasma Concentrations of Losmapimod and Food Effect of Losmapimod. Started Aug 2021; status: completed.
02
Drugs
losmapimod
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT05002231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05002231.